Clinical Roundup Libtayo + chemo significantly improve OS in advanced NSCLC September 24, 2021Vol.47 No.35
Clinical Roundup HER2-targeting antibody-drug improves PFS in deadly form of advanced breast cancer September 24, 2021Vol.47 No.35
Clinical Roundup Keytruda + chemo reduces risk of death by one-third vs. chemo as first-line treatment for persistent, recurrent, or metastatic cervical cancer September 24, 2021Vol.47 No.35
Clinical Roundup Tecentriq shows promise in treating early-stage lung cancer September 24, 2021Vol.47 No.35
Clinical Roundup MIT study finds global cancer risk from burning organic matter comes from unregulated chemicals September 24, 2021Vol.47 No.35
Clinical Roundup Four out of five cancer therapies tested in phase III trials do not achieve clinically-meaningful benefit in prolonging survival September 24, 2021Vol.47 No.35
Drugs & Targets Jakafi receives FDA approval for treatment of chronic GVHD September 24, 2021Vol.47 No.35
Drugs & Targets Cabometyx receives FDA approval for patients with previously treated radioactive iodine-refractory differentiated thyroid cancer September 24, 2021Vol.47 No.35
Drugs & Targets Brukinsa receives FDA accelerated approval for marginal zone lymphoma September 24, 2021Vol.47 No.35
Drugs & Targets Tivdak granted FDA accelerated approval for recurrent or metastatic cervical cancer September 24, 2021Vol.47 No.35
